GAMIDA CELL LTD (GMDA)
IL0011552663 - Common Stock
Top movers in Friday's after hours session
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to dive into all of the biggest pre-market stock movers that traders will want to keep an eye on Friday morning!
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of Directors
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic on Thursday as we check out all of the biggest stories moving shares this morning!
Trump Media (DJT) Stock Jumps 18% in Second Trading Day
Trump Media & Technology stock is on the rise Wednesday as shares of DJT continue to rally for the second day after going public.
GMDA Stock Earnings: Gamida Cell Beats EPS, Beats Revenue for Q4 2023
GMDA stock results show that Gamida Cell beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
GMDA Stock Earnings: Gamida Cell Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gamida Cell (NASDAQ:GMDA) just reported results for the fourth quarter of 2023....
Hedgeye Warns That Reddit (RDDT) Stock Will Fall 50%
Reddit stock is a hot topic among traders on Wednesday after one analyst warns that RDDT could give up 50% of its gains.
Why Is Gamida Cell (GMDA) Stock Down 82% Today?
Gamida Cell stock is falling on Wednesday with heavy trading of GMDA shares after the company announced plans to go private.
Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update
Company announces commencement of restructuring process supported by Highbridge Capital Management Continued progress of launch of Omisirge®...
Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management
Company expected to receive significant new capital from Highbridge to bolster the commercialization of allogeneic stem cell transplant Omisirge®...
Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results
BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics,...
Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
Expanded access program (EAP) data for omidubicel are consistent with Phase 3 trial results on rates of hematopoietic recovery and infections following...
Gamida Cell stock jumps as company explores strategic alternatives (NASDAQ:GMDA)
Gamida Cell's shares surge 24% as the cell therapy firm explores strategic alternatives such as asset sale or merger.
Gamida Cell Actively Pursuing Strategic Alternatives
BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today...
Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023
BOSTON, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, is...
Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference
BOSTON, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today...
Gamida Cell files for $150M mixed shelf (NASDAQ:GMDA)
Gamida Cell (NASDAQ:GMDA) on Wednesday filed a prospectus for a mixed securities shelf offering of up to $150M.This prospectus is not an offer to sell these...
Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update
Company continues to advance launch, reports initial revenue from Omisirge® (omidubicel-onlv) Company to host conference call today at 8:30 a.m....
Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Data further characterize the mechanism for Gamida Cell’s proprietary nicotinamide (NAM) technology’s expansion and enhancement of cells...
Gamida Cell Reports Preliminary Data from Phase 1 Study of Natural Killer (NK) Cell Therapy Candidate GDA-201
Gamida Cell Issues Update on Israel Operations
Gamida Cell to Present Corporate Highlights at 2023 Cell & Gene Meeting on the Mesa
